RBC Capital Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $35

Benzinga · 3d ago
RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and lowers the price target from $36 to $35.